- Home
- HQL vs CRVS Comparison
HQL vs CRVS Comparison
Compare HQL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- CRVS
- Stock Information
- Founded
- HQL 1992
- CRVS 2014
- Country
- HQL United States
- CRVS United States
- Employees
- HQL N/A
- CRVS N/A
- Industry
- HQL Investment Managers
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- HQL Finance
- CRVS Health Care
- Exchange
- HQL Nasdaq
- CRVS Nasdaq
- Market Cap
- HQL 440.3M
- CRVS 459.0M
- IPO Year
- HQL N/A
- CRVS 2016
- Fundamental
- Price
- HQL $16.88
- CRVS $8.25
- Analyst Decision
- HQL
- CRVS Strong Buy
- Analyst Count
- HQL 0
- CRVS 4
- Target Price
- HQL N/A
- CRVS $13.75
- AVG Volume (30 Days)
- HQL 120.9K
- CRVS 1.1M
- Earning Date
- HQL 01-01-0001
- CRVS 11-04-2025
- Dividend Yield
- HQL 11.56%
- CRVS N/A
- EPS Growth
- HQL N/A
- CRVS N/A
- EPS
- HQL 0.79
- CRVS N/A
- Revenue
- HQL N/A
- CRVS N/A
- Revenue This Year
- HQL N/A
- CRVS N/A
- Revenue Next Year
- HQL N/A
- CRVS N/A
- P/E Ratio
- HQL $17.08
- CRVS N/A
- Revenue Growth
- HQL N/A
- CRVS N/A
- 52 Week Low
- HQL $11.34
- CRVS $2.54
- 52 Week High
- HQL $14.37
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- HQL 56.19
- CRVS 63.53
- Support Level
- HQL $15.67
- CRVS $7.01
- Resistance Level
- HQL $17.10
- CRVS $8.31
- Average True Range (ATR)
- HQL 0.39
- CRVS 0.53
- MACD
- HQL -0.11
- CRVS 0.02
- Stochastic Oscillator
- HQL 55.50
- CRVS 88.11
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).